PRLD
Prelude·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PRLD
Prelude Therapeutics Incorporated
A clinical-stage precision oncology company that developing innovative drug candidates for cancer
Biological Technology
02/05/2016
09/25/2020
NASDAQ Stock Exchange
131
12-31
Common stock
175 Innovation Boulevard, Wilmington, Delaware 19805
--
Prelude Therapeutics Incorporated, founded in Delaware on February 5, 2016, is a clinical-stage precision oncology company dedicated to discovering and developing small molecule therapies optimized for key driving mechanisms of highly unmet cancer needs.
Company Financials
EPS
PRLD has released its 2025 Q3 earnings. EPS was reported at -0.26, versus the expected -0.35, beating expectations. The chart below visualizes how PRLD has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
PRLD has released its 2025 Q3 earnings report, with revenue of 6.50M, reflecting a YoY change of 116.67%, and net profit of -19.73M, showing a YoY change of 38.88%. The Sankey diagram below clearly presents PRLD's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
